Literature DB >> 1651415

Episodic occurrence of antibodies against the bovine leukemia virus Rex protein during the course of infection in sheep.

M A Powers1, D Grossman, L C Kidd, K Radke.   

Abstract

Infection by bovine leukemia virus (BLV) is characterized by a long clinical latency after which some individuals develop B-cell tumors. The contributions of the viral regulatory proteins Tax and Rex during clinical latency and disease are incompletely understood. To learn about Rex expression in the host, we used a sensitive immunoprecipitation assay to detect Rex antibodies throughout the course of BLV infection in sheep. Sixty percent of the infected animals produced Rex antibodies in intermittent episodes. This pattern differed markedly from that of antibodies to virion structural proteins, which were maintained in all animals throughout infection. Only one of two animals that developed tumors had detectable Rex antibodies at the time, although the other had previously demonstrated an especially strong Rex antibody response. We examined the Rex response in the context of BLV infection by comparing it with the frequency of circulating mononuclear blood cells that could transcribe BLV RNA or produce infectious virus. Episodes of Rex antibody occurrence followed some but not all increases in the number of BLV-transcribing cells. Since the appearance of circulating antibodies requires that the intracellular Rex protein be available to serve as antigen, the episodic pattern of occurrence of Rex antibodies could result from intermittent killing by virus-specific cytotoxic cells. Fluctuations in titer that were observed during some episodes of Rex response could be due to antibody retention by antigen present in lymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651415      PMCID: PMC248958     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Antibodies against AIDS proteins.

Authors:  Y Devash; K Reagan; D Wood; J Turner; M Parrington; C Y Kang
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

2.  The prevalence of antibody to p42 of HTLV-I among ATLL patients in comparison with healthy carriers in Japan.

Authors:  T Yokota; M J Cho; N Tachibana; M F McLane; K Takatsuki; T H Lee; N Mueller; M Essex
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

3.  Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals.

Authors:  G D Ehrlich; J B Glaser; M A Abbott; D J Slamon; D Keith; M Sliwkowski; J Brandis; E Keitelman; Y Teramoto; L Papsidero
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

4.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.

Authors:  P A Krieg; D A Melton
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

Review 5.  Cytotoxic T lymphocytes against HIV.

Authors:  B D Walker; F Plata
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

6.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.

Authors:  B Ensoli; G Barillari; S Z Salahuddin; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

7.  Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression.

Authors:  P Reiss; A De Ronde; J M Lange; F De Wolf; J Dekker; S A Danner; C Debouck; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

8.  Transient increases of blood mononuclear cells that could express bovine leukemia virus early after experimental infection of sheep.

Authors:  D M Lagarias; K Radke
Journal:  Microb Pathog       Date:  1990-09       Impact factor: 3.738

9.  Sexual transmission of human T-cell leukemia virus type I associated with the presence of anti-Tax antibody.

Authors:  Y M Chen; A Okayama; T H Lee; N Tachibana; N Mueller; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection.

Authors:  S Kamihira; K Toriya; T Amagasaki; S Momita; S Ikeda; Y Yamada; M Tomonaga; M Ichimaru; K Kinoshita; T Sawada
Journal:  Jpn J Cancer Res       Date:  1989-11
View more
  9 in total

1.  gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.

Authors:  P Lundberg; G A Splitter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1.

Authors:  O Orlik; J Ban; J Hlavaty; C Altaner; R Kettmann; D Portetelle; G A Splitter
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Pathogenicity of molecularly cloned bovine leukemia virus.

Authors:  J Rovnak; A L Boyd; J W Casey; M A Gonda; W A Jensen; G L Cockerell
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Activation of bovine leukemia virus transcription in lymphocytes from infected sheep: rapid transition through early to late gene expression.

Authors:  M A Powers; K Radke
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Bovine leukemia virus gene expression in vivo.

Authors:  L Haas; T Divers; J W Casey
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

6.  Identification of alternatively spliced mRNAs encoding potential new regulatory proteins in cattle infected with bovine leukemia virus.

Authors:  S Alexandersen; S Carpenter; J Christensen; T Storgaard; B Viuff; Y Wannemuehler; J Belousov; J A Roth
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

7.  A detailed molecular analysis of complete bovine leukemia virus genomes isolated from B-cell lymphosarcomas.

Authors:  Gonzalo Moratorio; Sabrina Fischer; Sergio Bianchi; Lorena Tomé; Gonzalo Rama; Gonzalo Obal; Federico Carrión; Otto Pritsch; Juan Cristina
Journal:  Vet Res       Date:  2013-03-18       Impact factor: 3.683

8.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

Review 9.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.